Centogene NV (CNTG) has released an update.
Centogene N.V. reveals groundbreaking data from its ROPAD Study, showing that 15% of Parkinson’s disease cases have a genetic basis, primarily involving mutations in LRRK2 and GBA1 genes. These insights, published in Brain Journal, highlight the potential for gene-targeted clinical trials and underscore the importance of genetic testing for advancing Parkinson’s disease treatment. The company’s extensive research and collaboration efforts aim to improve patient care and accelerate the development of gene-specific therapies.
For further insights into CNTG stock, check out TipRanks’ Stock Analysis page.
